Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-932 by AbbVie for Generalized Anxiety Disorder (GAD): Likelihood of Approval
ABBV-932 is under clinical development by AbbVie and currently in Phase I for Generalized Anxiety Disorder (GAD). According to GlobalData,...
ABBV-932 by AbbVie for Schizophrenia: Likelihood of Approval
ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs...
ABBV-932 by AbbVie for Bipolar Disorder (Manic Depression): Likelihood of Approval
ABBV-932 is under clinical development by AbbVie and currently in Phase I for Bipolar Disorder (Manic Depression). According to GlobalData,...